Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 4Colorectal Neoplasms 4Recurrence 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Prostatic Neoplasms 2Mesothelioma, Malignant 2Lung Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophagogastric Adenocarcinoma 1Endometrial Neoplasms 1

Interventions

Sorafenib 10Magnetic Resonance Spectroscopy 10trametinib 8lenvatinib 8dabrafenib 7pembrolizumab 6Nivolumab 6Iodine-131 6Everolimus 6Sunitinib 5Paclitaxel 5vandetanib 4apatinib 4Thyrotropin Alfa 4Doxorubicin 4selpercatinib 3anlotinib 3Specimen Handling 3Radiotherapy 3Ipilimumab 3Iodine-124 3Fluorodeoxyglucose F18 3Cisplatin 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2tipifarnib 2surufatinib 2spartalizumab 2pazopanib 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Neoplasms × nintedanib × Clear all
NCT01788982 2020-07-31

Nintedanib(BIBF1120) in Thyroid Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
100 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡